MyFibroScan

10 Tsg.+
Downloads
Altersfreigabe
Jedes Alter
Screenshot
Screenshot
Screenshot
Screenshot
Screenshot
Screenshot
Screenshot
Screenshot
Screenshot
Screenshot
Screenshot
Screenshot
Screenshot
Screenshot
Screenshot
Screenshot
Screenshot
Screenshot
Screenshot
Screenshot
Screenshot
Screenshot
Screenshot
Screenshot

Über diese App

FibroScan® is the non-invasive solution for comprehensive management of liver health.

Fibroscan® provides unique and patented biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 2500 peer-reviewed publications and 60+ international guidelines.

myFibroScan app is your everyday FibroScan® companion to access Interpretation Guide and FibroScan® based scores in an easy, fast and intuitive way :

The Interpretation Guide utilizes data from clinical studies to assist providers in interpreting Fibroscan® examination results.
Scores enhance Fibroscan® liver disease assessment with biological markers.
Scores are presented as educational services intended for licensed healthcare professionals. While the scores are about specific medical and healthcare issues, they are not a substitute for/or replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions.

- Agile™3+ is an aid to identify NAFLD patients with advanced fibrosis by combining VCTE™ and routine clinical parameters to reduce the need for liver biopsy. High clinical performances are demonstrated in large external validation cohorts from different geographical origins.

- Agile™4 is an aid to early identify NAFLD patients with cirrhosis by combining VCTE™ and routine clinical parameters. It can help the physicians to manage the disease to prevent liver-related complications such as hepatocellular carcinoma. High clinical performances are demonstrated in large external validation cohorts from different geographical origin.

- Fast™ is an aid to identify at risk NASH patients defined as NASH + NAS≥4 + F≥2. Good to excellent performance in cohorts from different clinical settings (NAFLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast™.
Aktualisiert am
22.04.2024

Datensicherheit

Was die Sicherheit angeht, solltest du nachvollziehen, wie Entwickler deine Daten erheben und weitergeben. Die Datenschutz- und Sicherheitspraktiken können je nach Verwendung, Region und Alter des Nutzers variieren. Diese Informationen wurden vom Entwickler zur Verfügung gestellt und können jederzeit von ihm geändert werden.
Keine Daten werden mit Drittunternehmen oder -organisationen geteilt
Diese App kann die folgenden Datentypen erheben
Personenbezogene Daten, App-Informationen und -Leistung und Geräte- oder andere IDs
Daten werden bei der Übertragung verschlüsselt
Du kannst das Löschen der Daten beantragen

Neuigkeiten

This new version will allow to be compatible with latest Play Store requirements